Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$132.26 USD
-4.27 (-3.13%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $132.81 +0.55 (0.42%) 7:24 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
Ascendis Pharma A/S [ASND]
Reports for Purchase
Showing records 101 - 120 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH/HP NDA Accepted for Priority Review, PDUFA Set for April 30, 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH U.S./EU Opportunity Opens Up with Natpara/Natpar Discontinuation by YE24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH Blockbuster Potential Coming into Focus; Adding to BIL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
110wk PaTH Forward OLE Results for TC-PTH/HP Highlight Durability of Response
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Wedbush Healthcare Conference - That''s A Wrap; Key Takeaways
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q2: SKYTROFA Sales SKYrocket; Multiple Value-Driving Catalysts in H2
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
E.N.D.O - Exploring New Drug Opportunities in Endocrinology KOL Call Highlights
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q1: SKYTROFA''s Shaky Start Not Surprising; Eyes on the Prize with TC-PTH/HP
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE- The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Model Update Ahead of Q1:22, Upcoming Catalysts
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Ascending to Greater Heights; Assuming at OUTPERFORM & $163 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Topline PaTHway Ph3 Results; Positive at First Blush but Further Clarity Needed
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L